Industry News
Xcell collaborators earn $1m NIH grant
Collaborators of Perth devices company Xcell Diagnostics (ASX:XEL) have received a US NIH grant worth more than AUD$1 million (US$702,000) to perform clinical studies on Xcell's Funhaler paediatric asthma spacer device. [ + ]
Researchers get a preview of synchrotron-based medical opportunities
More than 130 scientists and clinicians got a glimpse of synchrotron-based medicine at a recent workshop held at the Peter MacCallum Cancer Centre in Melbourne. [ + ]
Eiffel signs US insulin trial deal
Melbourne drug re-engineering company Eiffel Technologies (ASX:EIF) has signed an agreement with a large US drug-delivery company to trial an inhalable form of insulin produced by Eiffel's proprietary supercritical fluid technology. [ + ]
Worldwide recognition for researcher’s foresight
International honours have been bestowed on Charles Sturt University (CSU) Professor of Irrigation Graeme Batten for his leading research into the rapid, reliable and low cost analysis technique which has revolutionised crop management.
[ + ]Cerylid regroups, lays off staff
Unlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff. [ + ]
Feds let CSL supply deal lapse
The federal government made a decision more than a year ago not to take up an option to extend its contract with CSL for the supply of blood plasma products to Australian hospitals for another five years. [ + ]
Biotron adds dengue virus to discovery roster
Canberra biotechnology company Biotron (ASX: BIT) has added dengue virus to the lengthening list of potentially lethal human viruses that possess ion-channel genes. [ + ]
UK hints at end to drug price controls
The British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK. [ + ]
Agenix appoints new US vet distributor
Brisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US. [ + ]
Arthritis CRC picks up new funding and partners
The Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs. [ + ]
Compumedics revenues, losses up
Compumedics' (ASX:CMP) revenues for the 2002-2003 financial year were up 62 per cent to AUD$32 million, reflecting strong growth in the company's sleep diagnostics business. [ + ]
Anadis therapy aiming to ease travellers' paths
It's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip. [ + ]
Patent could lead to new royalty revenue: CSL
A new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US. [ + ]
Do you have hyperactive platelets?
A researcher at the University of Newcastle is looking for patients with type-2 diabetes who are currently not taking anti-platelet medication for a new study involving tomato juice and fish oil!
[ + ]PanBio tips profit for 2003-04
Queensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today. [ + ]
